Spruce Biosciences, Inc. (SPRB)
39.65
-1.82
(-4.39%)
USD |
NASDAQ |
Oct 16, 16:00
40.00
+0.35
(+0.88%)
After-Hours: 20:00
Spruce Biosciences Enterprise Value : 20.53M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 20.53M |
| October 15, 2026 | 25.54M |
| October 14, 2026 | 18.68M |
| October 13, 2026 | 22.45M |
| October 12, 2026 | 29.39M |
| October 09, 2026 | 32.64M |
| October 08, 2026 | 36.74M |
| October 07, 2026 | 33.60M |
| October 06, 2026 | 29.16M |
| October 05, 2026 | 36.41M |
| October 02, 2026 | 37.21M |
| October 01, 2026 | 34.62M |
| September 30, 2026 | 45.11M |
| September 29, 2026 | 41.50M |
| September 28, 2026 | 42.16M |
| September 25, 2026 | 45.49M |
| September 24, 2026 | 46.32M |
| September 23, 2026 | 47.41M |
| September 22, 2026 | 48.99M |
| September 21, 2026 | 59.20M |
| September 18, 2026 | 57.41M |
| September 17, 2026 | 59.64M |
| September 16, 2026 | 60.47M |
| September 15, 2026 | 63.24M |
| September 14, 2026 | 67.87M |
| Date | Value |
|---|---|
| September 11, 2026 | 59.20M |
| September 10, 2026 | 60.99M |
| September 09, 2026 | 64.82M |
| September 08, 2026 | 74.04M |
| September 04, 2026 | 70.85M |
| September 03, 2026 | 70.24M |
| September 02, 2026 | 75.64M |
| September 01, 2026 | 64.43M |
| August 31, 2026 | 73.71M |
| August 28, 2026 | 78.69M |
| August 27, 2026 | 85.63M |
| August 26, 2026 | 80.62M |
| August 25, 2026 | 85.90M |
| August 24, 2026 | 72.83M |
| August 21, 2026 | 53.37M |
| August 20, 2026 | 54.48M |
| August 19, 2026 | 57.17M |
| August 18, 2026 | 56.85M |
| August 17, 2026 | 57.06M |
| August 14, 2026 | 56.28M |
| August 13, 2026 | 48.38M |
| August 12, 2026 | 40.95M |
| August 11, 2026 | 39.13M |
| August 10, 2026 | 38.56M |
| August 07, 2026 | 40.40M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.409B |
| Alnylam Pharmaceuticals, Inc. | 30.68B |
| Anika Therapeutics, Inc. | 254.23M |
| Savara, Inc. | 771.40M |
| Vericel Corp. | 1.986B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.23M |
| Total Expenses (Quarterly) | 16.23M |
| EPS Diluted (Quarterly) | -6.676 |
| Earnings Yield | -103.1% |
| Normalized Earnings Yield | -97.93 |